ArticleMemorias do Instituto Oswaldo Cruz2026
Circulation of fluconazole-resistant Candida auris in Peru confirmed by genomic analysis.
Article in Memorias do Instituto Oswaldo Cruz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida auris is an emerging fungal pathogen associated with invasive infections, notable for nosocomial spread and multidrug resistance. Despite its public health importance, genetic data from Peruvian isolates remain limited.
objectivesTo perform a multi-isolate genomic analysis of Peruvian C. auris isolates, including epidemiological analysis, clade assignment, phylogenetic reconstruction, and characterisation of antifungal resistance-associated mutations.
methodsTwenty clinical samples from hospitals in Lima and Callao were identified using MALDI-TOF and subjected to antifungal susceptibility testing. Genomic DNA was sequenced, and genomes meeting quality criteria (n = 19) were included in the analysis. Phylogenomic and ERG11 phylogenetic analyses were performed, and protein modelling combined with molecular docking was used to assess interactions with lanosterol 14-α-demethylase.
findingsAll analysed isolates belonged to clade IV and exhibited resistance to fluconazole. The ERG11 gene harboured four relevant mutations; notably, K143R was located within the hemi-binding region of lanosterol 14-α-demethylase and was predicted, based on molecular docking, to potentially alter fluconazole binding. These findings highlight the circulation of a resistant clade and underscore the need for strengthened genomic surveillance and antifungal stewardship strategies. MAIN
conclusionsThis study expands the genomic data available for C. auris and reinforces the urgent need for sustained genomic surveillance to monitor and contain antifungal resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.